Immune cell therapy targets Hard-to-Treat scleroderma
NCT ID NCT07355972
First seen Jan 26, 2026 · Last updated May 13, 2026 · Updated 15 times
Summary
This early-phase study tests a new treatment called CT1195E CAR-T cells for people with severe systemic sclerosis (scleroderma) that hasn't responded to other therapies. The therapy uses a patient's own immune cells, modified to attack disease-causing cells. The study aims to find the safest dose and check if it can reduce disease activity. Only 12 adults aged 18-60 will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SSC-SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.